AU2013221502C1 - Recombinant poxviral vectors expressing both rabies and OX40 proteins, and vaccines made therefrom - Google Patents

Recombinant poxviral vectors expressing both rabies and OX40 proteins, and vaccines made therefrom Download PDF

Info

Publication number
AU2013221502C1
AU2013221502C1 AU2013221502A AU2013221502A AU2013221502C1 AU 2013221502 C1 AU2013221502 C1 AU 2013221502C1 AU 2013221502 A AU2013221502 A AU 2013221502A AU 2013221502 A AU2013221502 A AU 2013221502A AU 2013221502 C1 AU2013221502 C1 AU 2013221502C1
Authority
AU
Australia
Prior art keywords
seq
leu
dna
rabies
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013221502A
Other languages
English (en)
Other versions
AU2013221502B2 (en
AU2013221502A1 (en
Inventor
Frederic David
Teshome Mebatsion
Jules Maarten Minke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health USA Inc
Original Assignee
Boehringer Ingelheim Animal Health USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Animal Health USA Inc filed Critical Boehringer Ingelheim Animal Health USA Inc
Publication of AU2013221502A1 publication Critical patent/AU2013221502A1/en
Assigned to MERIAL, INC. reassignment MERIAL, INC. Request for Assignment Assignors: MERIAL LIMITED
Publication of AU2013221502B2 publication Critical patent/AU2013221502B2/en
Application granted granted Critical
Publication of AU2013221502C1 publication Critical patent/AU2013221502C1/en
Assigned to Boehringer Ingelheim Animal Health USA Inc. reassignment Boehringer Ingelheim Animal Health USA Inc. Request for Assignment Assignors: MERIAL, INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C12N15/8633—Avian poxviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013221502A 2012-02-14 2013-02-14 Recombinant poxviral vectors expressing both rabies and OX40 proteins, and vaccines made therefrom Ceased AU2013221502C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261598610P 2012-02-14 2012-02-14
US61/598,610 2012-02-14
PCT/US2013/026206 WO2013123242A1 (en) 2012-02-14 2013-02-14 Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom

Publications (3)

Publication Number Publication Date
AU2013221502A1 AU2013221502A1 (en) 2014-08-28
AU2013221502B2 AU2013221502B2 (en) 2017-10-26
AU2013221502C1 true AU2013221502C1 (en) 2018-03-01

Family

ID=47757705

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013221502A Ceased AU2013221502C1 (en) 2012-02-14 2013-02-14 Recombinant poxviral vectors expressing both rabies and OX40 proteins, and vaccines made therefrom

Country Status (12)

Country Link
US (2) US9567606B2 (enExample)
EP (2) EP2814506B1 (enExample)
JP (1) JP6260972B2 (enExample)
CN (1) CN104203271B (enExample)
AU (1) AU2013221502C1 (enExample)
BR (1) BR112014020019A8 (enExample)
CA (1) CA2864119C (enExample)
EA (1) EA032389B1 (enExample)
ES (2) ES2723273T3 (enExample)
MX (1) MX360415B (enExample)
NZ (2) NZ722700A (enExample)
WO (1) WO2013123242A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009111738A2 (en) 2008-03-06 2009-09-11 Mayo Foundation For Medical Education And Research Single cycle replicating adenovirus vectors
US9567606B2 (en) 2012-02-14 2017-02-14 Merial Inc. Recombinant poxviral vectors expressing both rabies and OX40 proteins, and vaccines made therefrom
US9974845B2 (en) 2013-02-22 2018-05-22 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
US10196435B2 (en) * 2013-11-18 2019-02-05 University Of Southern California OX40L fusion protein for the immunotherapy of tumors of veterinary animals
MX375528B (es) 2013-12-20 2025-03-06 Boehringer Ingelheim Vetmedica Gmbh Variante del virus prrs, clon de adnc del virus europeo y sus usos.
CN103877570B (zh) * 2014-02-19 2016-01-20 北京中联康生物科技有限公司 狂犬病活疫苗和制备狂犬病口服活疫苗的方法
ES2754239T3 (es) 2014-03-12 2020-04-16 Curevac Ag Combinación de vacunación y agonistas de OX40
US10010499B2 (en) 2014-11-03 2018-07-03 Merial Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
SG11201705844SA (en) 2015-02-06 2017-08-30 Heat Biologics Inc Vector co-expressing vaccine and costimulatory molecules
DK3458474T3 (da) 2016-05-18 2022-09-26 Modernatx Inc Kombinationer af mrna'er, der koder for immunmodulerende polypeptider og anvendelser deraf
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
CA3088646A1 (en) 2018-02-23 2019-08-29 Boehringer Ingelheim Vetmedica Gmbh Recombinant viral vector systems expressing exogenous feline paramyxovirus genes and vaccines made therefrom
US12042527B2 (en) 2019-01-08 2024-07-23 Modernatx, Inc. Use of mRNAs encoding OX40L, IL-23 and IL-36gamma in combination with immune checkpoint blockade for treating particular cancers
CN111518776A (zh) * 2020-04-16 2020-08-11 大理大学 一种重组狂犬病病毒疫苗株及其制备方法
GB202012331D0 (en) * 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
US11149286B1 (en) * 2020-08-17 2021-10-19 Mayo Foundation For Medical Education And Research Adenovirus vectors and methods for using adenovirus vectors
EP4476256A1 (en) * 2022-02-09 2024-12-18 Petmedix Ltd. Therapeutic antibodies
CN116656730B (zh) * 2023-05-25 2024-03-19 军事科学院军事医学研究院军事兽医研究所 一种表达狂犬病病毒g、m蛋白的重组金丝雀痘病毒及其构建方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
AU672359B2 (en) * 1991-03-07 1996-10-03 Virogenetics Corporation Genetically engineered vaccine strain
US6309647B1 (en) 1999-07-15 2001-10-30 Aventis Pasteur Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
FR2724385B1 (fr) 1994-08-29 1996-12-13 Rhone Merieux Vaccin de la peritonite infectieuse feline.
EP0826063A1 (en) 1995-04-25 1998-03-04 Vical Incorporated Single-vial formulations of dna/lipid complexes
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
FR2751228B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
CA2294793A1 (fr) 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
US6541458B1 (en) 1999-07-16 2003-04-01 Merial Feline calicivirus genes and vaccines in particular recombinant vaccines
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
JP2004517057A (ja) * 2000-11-03 2004-06-10 オックスフォード バイオメディカ（ユーケイ）リミテッド ベクターシステム
US7740863B2 (en) 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
US7582302B2 (en) 2004-06-04 2009-09-01 Merial Limited Needle-free administration of FeLV vaccines
DK1773387T3 (da) 2004-06-25 2013-07-15 Merial Ltd Avipox-rekombinanter der udtrykker mund- og klovesyge-virusgener
US8980280B2 (en) 2005-03-30 2015-03-17 Merial, Inc. Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene
SI1881845T1 (sl) 2005-04-25 2010-06-30 Merial Ltd Cepiva proti virusu Nipah
US7384642B2 (en) 2005-08-25 2008-06-10 Merial Limited Canine influenza vaccines
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
US8008268B2 (en) 2006-07-25 2011-08-30 Merial Limited Vaccines against vesicular stomatitis
US7910112B2 (en) 2006-11-06 2011-03-22 Merial Limited Feline vaccines against avian influenza
CA2670097C (en) 2006-11-21 2015-10-06 Merial Limited Prime boost canine leishmania vaccine
BRPI0920622B1 (pt) 2008-10-24 2019-11-12 Merial, Inc. vacina contra o vírus da doença equina africana
CN101884793A (zh) * 2010-06-29 2010-11-17 中国人民解放军第三军医大学 乙肝病毒核心抗原的免疫增强型基因疫苗及其制备方法
US9567606B2 (en) 2012-02-14 2017-02-14 Merial Inc. Recombinant poxviral vectors expressing both rabies and OX40 proteins, and vaccines made therefrom

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LUI et al, Vaccine, Vol. 27, page 5077-5084. 2009. *

Also Published As

Publication number Publication date
EA201400912A1 (ru) 2015-01-30
AU2013221502B2 (en) 2017-10-26
ES2723273T3 (es) 2019-08-23
US10006050B2 (en) 2018-06-26
BR112014020019A8 (pt) 2022-07-12
CA2864119C (en) 2022-05-24
ES2866108T3 (es) 2021-10-19
EP3466443A1 (en) 2019-04-10
AU2013221502A1 (en) 2014-08-28
EP2814506B1 (en) 2018-11-28
NZ628270A (en) 2016-09-30
CN104203271A (zh) 2014-12-10
CA2864119A1 (en) 2013-08-22
US20170137843A1 (en) 2017-05-18
NZ722700A (en) 2017-12-22
EP2814506A1 (en) 2014-12-24
EA032389B1 (ru) 2019-05-31
EP3466443B1 (en) 2020-12-16
US20130209511A1 (en) 2013-08-15
US9567606B2 (en) 2017-02-14
JP6260972B2 (ja) 2018-01-17
JP2015511948A (ja) 2015-04-23
BR112014020019A2 (pt) 2017-07-04
MX360415B (es) 2018-10-31
WO2013123242A1 (en) 2013-08-22
CN104203271B (zh) 2017-08-25
MX2014009845A (es) 2015-03-10
HK1200327A1 (en) 2015-08-07

Similar Documents

Publication Publication Date Title
AU2013221502C1 (en) Recombinant poxviral vectors expressing both rabies and OX40 proteins, and vaccines made therefrom
CN108348594B (zh) 犬科动物细小病毒(cpv)病毒样颗粒(vlp)疫苗及其用途
KR102606810B1 (ko) 오토펄린을 발현시키기 위한 조성물 및 방법
KR102077131B1 (ko) 치쿤구니야 바이러스 폴리펩티드를 발현하는 재조합 홍역 바이러스 및 이의 사용
KR20180081527A (ko) 클로스트리듐 박테리아의 형질전환을 위한 유전자 도구
HUE033886T2 (en) For the preparation and use of a recombinant bird-paramyxovirus vaccine and method
US20130302270A1 (en) Tumor targeted tnf-related apoptosis inducing ligand fusion polypeptide, methods and uses therefor
CN112048484A (zh) 一株表达传染性法氏囊强毒株vp2蛋白的基因ⅶ型新城疫重组病毒和疫苗
CN114231562A (zh) 一种表达荧光素酶基因的淋巴脉络丛脑膜炎病毒及其构建方法和应用
KR102335519B1 (ko) 인체 감염 사스코로나 바이러스 예방 및 감염 증상 완화용 백신 조성물
KR20210084596A (ko) 이종 스파이크 단백질을 갖는 h52 ibv 백신
JP2000350590A (ja) 成長ホルモン及び成長ホルモン放出ホルモン組成物
CN116763909B (zh) 小檗碱与her2-car-t细胞联合制备治疗骨肉瘤的药物
CN116726153A (zh) 雷公藤红素与her2-car-t细胞联合制备治疗骨肉瘤的药物
CN110819657B (zh) 一种减毒棒状病毒的制备方法及应用
CN116726154B (zh) 五味子乙素与her2-car-t细胞联合制备治疗骨肉瘤的药物
AU2012284558A1 (en) Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene
CN114703207A (zh) 重组质粒的制备方法和重组病毒
KR101876486B1 (ko) Myh4 유전자를 포함하는 재조합 벡터 및 이의 이용
CN116785417A (zh) 芦荟苷与her2-car-t细胞联合制备治疗骨肉瘤的药物
CN113215194B (zh) 一种监测海水重金属的转荧光蛋白基因海水青鳉的制作与应用
CN114807210B (zh) 一种基于细胞质线性质粒的t7表达系统及其在酵母中表达蛋白质的方法
RU2777400C2 (ru) Рекомбинантные непатогенные конструкции вируса болезни марека, кодирующие антигены вируса инфекционного ларинготрахеита и вируса инфекционного бурсита
HK40007462B (en) Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom
HK40007462A (en) Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: MERIAL, INC.

Free format text: FORMER APPLICANT(S): MERIAL LIMITED

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 11 OCT 2017

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 11 OCT 2017

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.

Free format text: FORMER OWNER(S): MERIAL, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired